A plain-English look at the clinical evidence behind TSM, including the COMBINE study, Finnish trials, and real-world outcomes.
Educational Information Only
Not a substitute for medical advice. Always consult a licensed clinician.
The Sinclair Method is sometimes described as "controversial" or "not widely accepted." This framing is misleading. The underlying medication — naltrexone — has been FDA-approved for alcohol use disorder since 1994, and the evidence base for its effectiveness is substantial. What is less widely known is the specific protocol that constitutes the Sinclair Method: naltrexone taken before drinking, rather than daily.
Here is a plain-English look at what the research actually says.
The Sinclair Method is named after Dr. John David Sinclair, a Finnish neuroscientist who spent decades studying alcohol dependence and the opioid system. His key insight — published in a landmark 2001 paper in Alcohol and Alcoholism — was that naltrexone produces different outcomes depending on when it is taken.
When naltrexone is taken daily regardless of drinking, it supports abstinence but does not produce pharmacological extinction — the gradual unlearning of the alcohol reward association. When taken specifically before drinking, it blocks the reward signal during the drinking experience, allowing extinction to occur over time.
Sinclair's animal studies demonstrated this principle clearly: rats trained to drink alcohol showed dramatic reductions in drinking when given naltrexone before drinking sessions, but not when given naltrexone without drinking opportunities.
The COMBINE study, published in JAMA in 2006, is one of the largest clinical trials of alcohol use disorder treatments ever conducted. It enrolled 1,383 patients across 11 US academic sites and tested various combinations of naltrexone, acamprosate, and behavioral therapies.
Key findings relevant to naltrexone:
Finland has been at the forefront of TSM research and implementation. The Finnish Social Insurance Institution approved naltrexone for alcohol use disorder in the 1990s, and Finnish clinicians have accumulated significant real-world data on the Sinclair Method protocol.
A 2001 study by Heinälä et al. in Alcoholism: Clinical and Experimental Research specifically tested the targeted (pre-drinking) naltrexone protocol versus daily naltrexone versus placebo. The targeted protocol showed advantages in reducing heavy drinking days and in producing extinction-like patterns of reduced drinking over time.
A 2014 Cochrane systematic review of naltrexone for alcohol use disorder analyzed 53 randomized controlled trials involving 9,140 patients. Key findings:
Honesty about the limitations of the evidence is important. Most large clinical trials have tested daily naltrexone rather than the specific pre-drinking protocol of the Sinclair Method. The evidence for the targeted protocol is promising but based on a smaller body of research than daily naltrexone.
Additionally, naltrexone does not work equally well for everyone. Research has identified genetic factors — particularly variants of the OPRM1 gene (the A118G polymorphism) — that may predict naltrexone response. People with the G allele variant appear to respond more strongly to naltrexone. This area of research is ongoing.
The evidence base for naltrexone in alcohol use disorder is robust. The specific Sinclair Method protocol has a smaller but meaningful evidence base, grounded in a well-understood neurobiological mechanism. The medication is FDA-approved, non-addictive, and has a well-characterized side effect profile.
What the research does not do is make treatment decisions for individuals. Whether naltrexone and the Sinclair Method are appropriate for any given person depends on their medical history, drinking patterns, goals, and individual circumstances — and requires evaluation by a licensed clinician.